SCHEMBL1121618

SCHEMBL1121618

O=C(Cc1ccc(F)cc1Br)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.46
MAPT P10636 3/20 0.46
PKM P14618 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
NPC1 O15118 2/20 0.46
PTPN1 P18031 2/20 0.43
GSK3B P49841 2/20 0.43
KMT2A Q03164 5/20 0.41
MEN1 O00255 3/20 0.41
MAPK1 P28482 2/20 0.41
CYP3A4 P08684 2/20 0.41
KDM4E B2RXH2 2/20 0.41
HPGD P15428 1/20 0.41
ALOX15 P16050 1/20 0.41
CES1 P23141 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
HSD11B1 P28845 1/20 0.40
ALDH1A1 P00352 2/20 0.39
P2RX7 Q99572 1/20 0.39
TRPA1 O75762 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27625170 0.83 GSK3B (0.46) RAB9AMAPTSMN1; SMN2NPC1PTPN1
SCHEMBL966965 0.83 SIGMAR1 (0.46) RAB9AMAPTSMN1; SMN2NPC1PTPN1
SCHEMBL909444 0.81 PKM (0.53) RAB9AMAPTPKMSMN1; SMN2NPC1
SCHEMBL29814973 0.81 PKM (0.53) RAB9AMAPTPKMSMN1; SMN2NPC1
SCHEMBL3097072 0.81 MEN1 (0.47) MAPTKMT2AMEN1MAPK1CYP3A4
SCHEMBL1121619 0.80 ALDH1A1 (0.52) RAB9AMAPTSMN1; SMN2NPC1PTPN1
SCHEMBL2936987 0.79 GSK3B (0.52) RAB9AMAPTSMN1; SMN2NPC1PTPN1
SCHEMBL157139 0.76 P2RX7 (0.45) MAPTPKMMAPK1CYP3A4KDM4E
SCHEMBL1345638 0.76 P2RX7 (0.45) PKMP2RX7
SCHEMBL1344059 0.76 P2RX7 (0.45) RAB9AMAPTPKMSMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102702014-A Method for preparing atorvastatin calcium intermediate YANGZIJIANG PHARMACEUTICAL GROUP JIANGSU HAICI BIOLOG PHARMACEUTICAL CO LTD 2012-10-03 CN disclosed
EP-1685100-B1 NOVEL 1, 3-DISUBSTITUTED AZETIDINE DERIVATIVES FOR USE AS 5HT2A RECEPTOR LIGANDS MERCK SHARP & DOHME (GB) 2011-02-09 EP disclosed
US-7094777-B2 5-HT2A receptor ligands MERK SHARP & DOHME LTD. 2006-08-22 US disclosed
EP-1685100-A1 NOVEL 1, 3-DISUBSTITUTED AZETIDINE DERIVATIVES FOR USE AS 5HT2A RECEPTOR LIGANDS Merck Sharp & Dohme Limited (GB) 2006-08-02 EP disclosed
WO-2005047247-A1 NOVEL1,3-DISUBSTITUTED AZETIDINE DERIVATIVES FOR USE AS 5HT2A RECEPTOR LIGANDS MERCK SHARP & DOHME LIMITED (GB) 2005-05-26 WO disclosed
WO-2005047246-A1 NOVEL 1, 3-DISUBSTITUTED AZETIDINE DEIVATIVES FOR USE AS 5HT2A RECEPTOR LIGANDS MERCK SHARP & DOHME LIMITED (GB) 2005-05-26 WO disclosed
US-20050101586-A1 Novel 5-HT2A receptor ligands MERCK SHARP & DOHME LTD. (GB) 2005-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101586-A1 Novel 5-HT2A receptor ligands HTR2A, HTR1A, HTR5A RAB9A 1740/4885MAPT 1845/4885PKM 3713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.